Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 7/20 | 0.40 |
| ▸ | PNP | P00491 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PYGL | P06737 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9293545 | 1.00 | SLC5A2 (0.40) | SLC5A2PNPALDH1A1PYGL | |
| SCHEMBL1022027 | 1.00 | SLC5A2 (0.40) | SLC5A2PNPALDH1A1PYGL | |
| SCHEMBL16620686 | 1.00 | SLC5A2 (0.40) | SLC5A2PNPALDH1A1PYGL | |
| SCHEMBL4293687 | 0.77 | KDM4E (0.49) | SLC5A2PNPALDH1A1 | |
| SCHEMBL24420223 | 0.75 | TK1 (0.39) | — | |
| SCHEMBL1996325 | 0.75 | PNP (0.43) | SLC5A2PNP | |
| SCHEMBL1675551 | 0.75 | TK1 (0.39) | — | |
| SCHEMBL18080095 | 0.75 | PYGL (0.43) | SLC5A2PYGL | |
| SCHEMBL17329460 | 0.75 | PNP (0.44) | SLC5A2PNPPYGL | |
| SCHEMBL21847661 | 0.75 | PNP (0.44) | SLC5A2PNPPYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960543-B2 | Nucleoside or nucleotide derivative and use thereof | RIKEN (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090275017-A1 | Novel Nucleoside or Nucleotide Derivative and Use Thereof | RIKEN (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1816130-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVE AND USE THEREOF | Riken (JP) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275017-A1 | Novel Nucleoside or Nucleotide Derivative and Use Thereof | DUT, NT5C3B, NT5C | SLC5A2 1291/4885PNP 52/4885ALDH1A1 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.